Sentiment-Signal
18,9
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 20.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
| 21.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
| 04.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
| 16.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers; Compensato |
| 21.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
Stammdaten
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Unternehmen & Branche
| Name | Roivant Sciences Ltd. |
|---|---|
| Ticker | ROIV |
| CIK | 0001635088 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 20,01 Mrd. USD |
| Beta | 1,21 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | 1,999,000 | -265,891,000 | -0.38 | 5,225,368,000 | 4,269,255,000 |
| 2025-09-30 | 10-Q | 1,571,000 | -113,519,000 | -0.17 | 5,062,598,000 | 4,362,331,000 |
| 2025-06-30 | 10-Q | 2,170,000 | -223,355,000 | -0.33 | 5,032,602,000 | 4,345,634,000 |
| 2025-03-31 | 10-K | 29,053,000 | -171,981,000 | -0.24 | 5,436,940,000 | 4,687,605,000 |
| 2024-12-31 | 10-Q | 9,018,000 | 169,381,000 | 0.23 | 5,792,345,000 | 5,189,472,000 |
| 2024-09-30 | 10-Q | 4,475,000 | -230,184,000 | -0.31 | 6,206,028,000 | 5,152,955,000 |
| 2024-06-30 | 10-Q | 7,990,000 | 95,297,000 | 0.12 | 6,496,448,000 | 5,435,309,000 |
| 2024-03-31 | 10-K | 32,713,000 | 4,348,926,000 | 5.23 | 7,222,482,000 | 5,968,581,000 |
| 2023-12-31 | 10-Q | 15,562,000 | 5,096,184,000 | 6.03 | 7,312,679,000 | 6,089,763,000 |
| 2023-09-30 | 10-Q | 3,648,000 | -304,327,000 | -0.40 | 2,065,543,000 | 948,534,000 |
| 2023-06-30 | 10-Q | 21,624,000 | -291,816,000 | -0.38 | 2,136,646,000 | 910,730,000 |
| 2023-03-31 | 10-K | 31,530,000 | -1,009,030,000 | -1.42 | 2,389,604,000 | 1,157,766,000 |
| 2022-12-31 | 10-Q | 17,052,000 | -352,014,000 | -0.49 | 2,202,960,000 | 955,520,000 |
| 2022-09-30 | 10-Q | 12,533,000 | -291,590,000 | -0.42 | 2,215,534,000 | 1,160,601,000 |
| 2022-06-30 | 10-Q | 4,319,000 | -331,809,000 | -0.48 | 2,600,398,000 | 1,384,111,000 |
| 2022-03-31 | 10-K | 55,286,000 | -845,262,000 | -1.26 | 2,585,129,000 | 1,656,944,000 |
| 2021-12-31 | 10-Q | 24,341,000 | -284,536,000 | -0.41 | 2,799,375,000 | 1,865,720,000 |
| 2021-09-30 | 10-Q | 13,987,000 | -208,481,000 | -0.32 | 3,102,906,000 | 2,038,015,000 |
| 2021-06-30 | 10-Q | 7,735,000 | -82,183,000 | -0.13 | 2,454,697,000 | 1,723,122,000 |
| 2021-03-31 | 10-K | 23,795,000 | -809,234,000 | 2,589,692,000 | 1,797,788,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200,000 | 29.59 | -5,918,000.00 | -43,0% | |
| 2026-04-16 | Gline Matthew | Director, Officer, CEO | Open Market Sale | -289,774 | 29.16 | -8,449,809.84 | -61,4% | |
| 2026-04-08 | Humes Jennifer | Officer, Chief Accounting Officer | Open Market Sale | -13,538 | 28.37 | -384,073.06 | -2,8% | |
| 2026-03-26 | Fitzgerald Meghan | Director | Open Market Sale | -70,000 | 27.45 | -1,921,500.00 | -14,0% | |
| 2026-03-16 | Epperly Melissa B, | Director | Open Market Sale | -41,861 | 28.68 | -1,200,573.48 | -8,7% | |
| 2026-02-23 | Torti Frank | Officer, President and Vant Chair | Open Market Sale | -587,390 | 27.51 | -16,159,098.90 | -117,5% | |
| 2026-02-20 | Torti Frank | Officer, President and Vant Chair | Open Market Sale | -1,012,610 | 27.15 | -27,492,361.50 | -199,9% | |
| 2026-02-19 | Torti Frank | Officer, President and Vant Chair | Open Market Sale | -1,400,000 | 27.42 | -38,388,000.00 | -279,1% | |
| 2026-02-13 | Venker Eric | Officer, President & Immunovant CEO | Open Market Sale | -200,000 | 26.49 | -5,298,000.00 | -38,5% | |
| 2026-02-09 | Sukhatme Mayukh | Director, Officer, President & CIO | Open Market Sale | -339,441 | 26.47 | -8,985,003.27 | -65,3% | |
| 2025-12-15 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -353,745 | 22.05 | -7,800,077.25 | -56,7% | |
| 2025-12-12 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -1,975,858 | 21.96 | -43,389,841.68 | -315,5% | |
| 2025-12-11 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -774,142 | 21.64 | -16,752,432.88 | -121,8% | |
| 2025-11-17 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -539,650 | 20.51 | -11,068,221.50 | -80,5% | |
| 2025-11-14 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -1,027,670 | 20.33 | -20,892,531.10 | -151,9% | |
| 2025-11-13 | Ramaswamy Vivek | 10% Owner | Open Market Sale | -287,283 | 20.81 | -5,978,359.23 | -43,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.